Division of Systems Toxicology, HFT-230, National Center for Toxicological Research, US FDA, 3900 NCTR Road, Jefferson, AR 72079-4502, USA.
Biomark Med. 2009 Oct;3(5):605-15. doi: 10.2217/bmm.09.43.
Incomplete knowledge of tissue pathogenesis is hampering the identification of biomarkers for the appropriate therapeutic targets to prevent or inhibit disease processes, and the prediction and diagnosis of injury due to disease and adverse events of drug therapy. The revolution in genomics and metabolomics, combined with advanced bioinformatics and computational methods for mining such large, complex data sets, are beginning to provide critical insights into tissue injury. Such results will move us closer to the promise of personalized medicine.
对组织发病机制的不完全了解阻碍了生物标志物的鉴定，这些生物标志物是为了预防或抑制疾病进程，以及预测和诊断因疾病和药物治疗不良事件而导致的损伤的适当治疗靶点。基因组学和代谢组学的革命，加上用于挖掘这些大型复杂数据集的先进生物信息学和计算方法，开始为组织损伤提供重要的见解。这些结果将使我们更接近个性化医疗的承诺。
